7 results on '"Shinjo, Samuel K."'
Search Results
2. Work situation, work ability and expectation of returning to work in patients with systemic autoimmune myopathies.
- Author
-
Cordeiro, Rafael A, Fischer, Frida M, and Shinjo, Samuel K
- Subjects
EMPLOYEE psychology ,WORK environment ,MUSCLE diseases ,CONFIDENCE intervals ,CROSS-sectional method ,WORK capacity evaluation ,AUTOIMMUNE diseases ,REGRESSION analysis ,DIABETES ,CUTANEOUS manifestations of general diseases ,SEX distribution ,FIBROMYALGIA ,SEVERITY of illness index ,SELF-efficacy ,RESEARCH funding ,QUESTIONNAIRES ,BODY movement ,DESCRIPTIVE statistics ,EMPLOYMENT reentry ,ANXIETY ,JOB performance ,EDUCATIONAL attainment ,ADULTS ,MIDDLE age - Abstract
Objectives To document the work situation, the work ability and the expectation of returning to work among adult patients with systemic autoimmune myopathies (SAMs), and to identify the factors associated with each of these outcomes. Methods Cross-sectional study. The work situation (performing paid work vs out of work) was ascertained via a structured questionnaire. For those who were working, we applied the Work Ability Index (WAI; scale 7–49); and for those who were out of work, we applied the Return-to-Work Self-Efficacy questionnaire (RTW-SE; scale 11–66). Results Of the 75 patients with SAMs included, 33 (44%) were doing paid work and 42 (56%) were out of work. The work situation was independently associated with physical function, assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI). A 1-point increase in the HAQ-DI (scale 0–3) decreased the chance of doing paid work by 66% (95% CI: 0.16, 0.74; P = 0.007). Patients performing paid work had a mean WAI of 33.5 (6.9). The following variables were associated with a decrease in the WAI score in the regression model: female sex (−5.04), diabetes (−5.94), fibromyalgia (−6.40), fatigue (−4.51) and severe anxiety (−4.59). Among those out of work, the mean RTW-SE was 42.8 (12.4). Cutaneous manifestations and >12 years of education were associated with an average increase of 10.57 and 10.9 points, respectively, in the RTW-SE. A 1-point increase in the HAQ-DI decreased the RTW-SE by 4.69 points. Conclusion Our findings highlight the poor work participation in a well-characterized sample of working-age patients with SAMs. Strategies to improve work-related outcomes in these patients are urgently needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
- Author
-
Aikawa, Nadia E, Kupa, Leonard V K, Silva, Clovis A, Saad, Carla G S, Pasoto, Sandra G, Yuki, Emily F N, Fusco, Solange R G, Shinjo, Samuel K, Andrade, Danieli C O, Sampaio-Barros, Percival D, Pereira, Rosa M R, Chasin, Anna C S, Shimabuco, Andrea Y, Luppino-Assad, Ana P, Leon, Elaine P, Lopes, Marta H, Antonangelo, Leila, Medeiros-Ribeiro, Ana C, and Bonfa, Eloisa
- Subjects
RITUXIMAB ,HUMAN research subjects ,IMMUNOGLOBULINS ,CONFIDENCE intervals ,COVID-19 vaccines ,MULTIPLE regression analysis ,MULTIVARIATE analysis ,AUTOIMMUNE diseases ,FISHER exact test ,MANN Whitney U Test ,VACCINE effectiveness ,INFORMED consent (Medical law) ,T-test (Statistics) ,MESSENGER RNA ,DESCRIPTIVE statistics ,RESEARCH funding ,RHEUMATISM ,PREDNISONE ,DATA analysis ,ODDS ratio ,DATA analysis software - Abstract
Objectives To assess immunogenicity of a heterologous fourth dose of an mRNA (BNT162b2) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in autoimmune rheumatic diseases (ARD) patients with poor/non-response to inactivated vaccine (Sinovac-CoronaVac). Methods A total of 164 ARD patients who were coronavirus disease 2019 (COVID-19) poor/non-responders (negative anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies—NAb) to the third dose of Sinovac-CoronaVac received an additional heterologous dose of mRNA (BNT162b2) 3 months after last dose. IgG and NAb were evaluated before and after the fourth dose. Results Significant increases were observed after the fourth dose in IgG (66.4 vs 95.1%, P < 0.001), NAb positivity (5.5 vs 83.5%, P < 0.001) and geometric mean titre (29.5 vs 215.8 AU/ml, P < 0.001), and 28 (17.1%) remained poor/non-responders. Patients with negative IgG after a fourth dose were more frequently under rituximab (P = 0.001). Negative NAb was associated with older age (P = 0.015), RA (P = 0.002), SSc (P = 0.026), LEF (P = 0.016) and rituximab use (P = 0.007). In multiple logistic regression analysis, prednisone dose ≥7.5 mg/day (OR = 0.34; P = 0.047), LEF (OR = 0.32, P = 0.036) and rituximab use (OR = 0.19, P = 0.022) were independently associated with negative NAb after the fourth vaccine dose. Conclusions This is the largest study to provide evidence of a remarkable humoral response after the fourth dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/non-response to the third dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov , CoronavRheum #NCT04754698. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Author
-
Shinjo, Samuel K, primary, de Souza, Fernando H C, additional, Borges, Isabela B P, additional, dos Santos, Alexandre M, additional, Miossi, Renata, additional, Misse, Rafael G, additional, Medeiros-Ribeiro, Ana C, additional, Saad, Carla G S, additional, Yuki, Emily F N, additional, Pasoto, Sandra G, additional, Kupa, Léonard V K, additional, Ceneviva, Carina, additional, Seraphim, Júlia C, additional, Pedrosa, Tatiana N, additional, Vendramini, Margarete B G, additional, Silva, Clóvis A, additional, Aikawa, Nádia E, additional, and Bonfá, Eloisa, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
- Author
-
Shinjo, Samuel K, Souza, Fernando H C de, Borges, Isabela B P, Santos, Alexandre M dos, Miossi, Renata, Misse, Rafael G, Medeiros-Ribeiro, Ana C, Saad, Carla G S, Yuki, Emily F N, Pasoto, Sandra G, Kupa, Léonard V K, Ceneviva, Carina, Seraphim, Júlia C, Pedrosa, Tatiana N, Vendramini, Margarete B G, Silva, Clóvis A, Aikawa, Nádia E, and Bonfá, Eloisa
- Subjects
- *
AUTOIMMUNE disease prevention , *MUSCLE diseases , *COVID-19 , *CLINICAL trials , *IMMUNOGLOBULINS , *CONFIDENCE intervals , *COVID-19 vaccines , *IMMUNOCOMPROMISED patients , *SEROCONVERSION , *IMMUNOSUPPRESSION , *SYMPTOMS , *DESCRIPTIVE statistics , *PATIENT safety , *LONGITUDINAL method , *COMORBIDITY - Abstract
Objectives To evaluate immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in systemic autoimmune myopathies (SAMs) and the possible influence of baseline disease parameters, comorbidities and therapy on immune response. Methods This prospective controlled study included 53 patients with SAMs and 106 non-immunocompromised control group (CTRL). All participants received two doses of the Sinovac-CoronaVac vaccine (28-day interval). Immunogenicity was assessed by anti-SARS-CoV-2 S1/S2 IgG seroconversion (SC), anti-S1/S2 IgG geometric mean titre (GMT), factor increase GMT (FI-GMT), neutralizing antibodies (NAb) positivity, and median neutralizing activity after each vaccine dose (D0 and D28) and six weeks after the second dose (D69). Participants with pre-vaccination positive IgG serology and/or NAb and those with RT-PCR confirmed COVID-19 during the protocol were excluded from immunogenicity analysis. Results Patients and CTRL had comparable sex (P> 0.99) and age (P= 0.90). Immunogenicity of 37 patients and 79 CTRL-naïve participants revealed at D69, a moderate but significantly lower SC (64.9% vs 91.1%, P< 0.001), GMT [7.9 (95%CI 4.7–13.2) vs 24.7 (95%CI 30.0–30.5) UA/ml, P< 0.001] and frequency of NAb (51.4% vs 77.2%, P< 0.001) in SAMs compared with CTRL. Median neutralizing activity was comparable in both groups [57.2% (interquartile range (IQR) 43.4–83.4) vs 63.0% (IQR 40.3–80.7), P= 0.808]. Immunosuppressives were less frequently used among NAb+ patients vs NAb- patients (73.7% vs 100%, P= 0.046). Type of SAMs, disease status, other drugs or comorbidities did not influence immunogenicity. Vaccine-related adverse events were mild with similar frequencies in patients and CTRL (P> 0.05). Conclusion Sinovac-CoronaVac is safe and has a moderate short-term immunogenicity in SAMs, but reduced compared with CTRL. We further identified that immunosuppression is associated with diminished NAb positivity. Trial registration COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS (CoronavRheum), http://clinicaltrials.gov/ct2/show/NCT04754698 [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis
- Author
-
Hoff, Leonardo S, primary, de Souza, Fernando H C, additional, Miossi, Renata, additional, and Shinjo, Samuel K, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Long-term effects of early pulse methylprednisolone and intravenous immunoglobulin in patients with dermatomyositis and polymyositis.
- Author
-
Hoff, Leonardo S, Souza, Fernando H C de, Miossi, Renata, and Shinjo, Samuel K
- Subjects
THERAPEUTIC use of immunoglobulins ,METHYLPREDNISOLONE ,INTRAVENOUS therapy ,DERMATOMYOSITIS ,POLYMYOSITIS ,CONFIDENCE intervals ,TIME ,MULTIVARIATE analysis ,RETROSPECTIVE studies ,AUTOIMMUNE diseases ,TREATMENT effectiveness ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,MYOSITIS ,DATA analysis software ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
Objective To evaluate the long-term effects of pulse i.v. methylprednisolone (IVMP) or IVIG administered during the first year of diagnosis in DM and PM patients. Methods This is a retrospective single-centre cohort study of patients with PM/DM followed for up to 4 years from 2001 to 2017. We used Cox regression models to estimate hazard ratios (HRs) and assess the effects of early pulse IVMP or IVIG on three outcomes: complete clinical response, CS discontinuation, and survival. Analysis was adjusted for clinical, laboratory and treatment covariates. Results A total of 204 patients were included and categorized into four initial treatment groups: pulse IVMP (n = 46), pulse IVMP + IVIG (n = 55), IVIG (n = 10), and without IVMP or IVIG (n = 93). The groups of early pulse IVMP and pulse IVMP + IVIG had a higher HR for complete clinical response in the multivariate models (HR = 1.56, 95% CI: 1.05, 2.33, P = 0.029; and HR = 1.58, 95% CI: 1.02, 2.45, P = 0.041, respectively). Only the group of pulse IVMP + IVIG had a significant association with CS discontinuation in the multivariate analysis (HR = 1.65, 95% CI: 1.02, 2.68, P = 0.043). Early pulse IVMP or IVIG had no impact on mortality. Conclusion Despite having a more severe disease profile, patients with PM/DM submitted to pulse IVMP or pulse IVMP + IVIG during the first year of diagnosis had a higher HR for complete clinical response, whereas the combination of pulse IVMP + IVIG had an association with CS discontinuation. Prospective long-term studies are warranted to confirm these benefits of early pulse IVMP and IVIG on patients with PM/DM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.